Market Overview

7 Biggest Price Target Changes For Tuesday

Share:
  • UBS lowered the price target for The Hershey Company (NYSE: HSY) from $106 to $90. Hershey shares closed at $99.36 on Monday.
  • Piper Jaffray boosted the price target for Ulta Beauty, Inc. (NASDAQ: ULTA) from $212 to $236. Ulta Beauty shares closed at $212.15 on Monday.
  • J.P. Morgan raised the price target on Netflix, Inc. (NASDAQ: NFLX) from $285 to $328. Netflix shares closed at $289.93 on Monday.
  • KeyBanc cut Alibaba Group Holding Limited (NYSE: BABA) price target from $228 to $219. Alibaba shares closed at $169.87 on Monday.
  • MKM Partners lowered L Brands, Inc. (NYSE: LB) price target from $48 to $42. L Brands shares closed at $38.06 on Monday.
  • J.P. Morgan boosted the price target for IAC/InterActiveCorp (NASDAQ: IAC) from $170 to $190. IAC/InterActiveCorp shares closed at $151.89 on Monday.
  • RBC Capital cut Radian Group Inc. (NYSE: RDN) price target from $28 to $19. Radian shares closed at $16.11 on Monday.

Posted-In: Price Target ChangesPrice Target Intraday Update Analyst Ratings

 

Related Articles (HSY + BABA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MDRXKeyBancUpgrades0.0
ANETNomuraUpgrades260.0
CNPRBC CapitalUpgrades34.0
FISVOppenheimerUpgrades88.0
FNDUBSUpgrades37.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Icahn Sells Federal-Mogul; Tenneco To Create Two Public Companies

Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer's Trial